Kantum Pharma Founder to Present Preclinical Data Demonstrating Beneficial Effects of P2Y14 Antagonist in Acute Kidney Injury at the American Society of Nephrology Annual MeetingNov 4, 2019
November 4, 2019 3:30pm Eastern Daylight Time
CAMBRIDGE, MA (Newswire.com) – Kantum Pharma Inc., a biopharmaceutical company focused on developing therapies for the prevention and treatment of damaging inflammation triggered by innate immunity, announced today that the Company’s scientific founder, Dr. Sylvie Breton, will present her lab’s groundbreaking research characterizing a key pathway responsible for initiating renal inflammation and a therapeutic approach for preventing Acute Kidney Injury (AKI).
Title: The P2Y14 Receptor: Linking the Intercalated Cell to Immune Defense
Presenter: Sylvie Breton, PhD, Professor of Medicine at Harvard Medical School
Time: Thursday, November 7, at 3:30 p.m.
Location: 146 C, Walter E. Washington Convention Center
Dr. Breton’s presentation will cover the elucidation of the P2Y14 purinergic receptor’s role in initiating renal inflammation and the beneficial effects of administering a P2Y14 antagonist to attenuate kidney inflammation and damage. This work provided the scientific rationale for Kantum’s lead program, KB-1801, which is being developed for the prevention of Cardiac Surgery-Associated Acute Kidney Injury.